En nyt vielä lähtisi henkseleitä paukutteleen, kunnes saadaan 2 annoksen taso tuonne 50+ % Suomessa 
Vaikka onhan se tilanne paljon parempi.
According to the latest figures from Public Health England (PHE), four weeks after one dose, either vaccine offered almost 50% protection against the Alpha variant. However for the Delta variant this protection was lower, with one dose of the Pfizer/BioNTech jab offering about 36% protection against symptomatic disease. For one dose of the Oxford/AstraZeneca vaccine this figure was about 30%.
Two weeks after the second dose, the differences in vaccine effectiveness by variant were more modest, with the Pfizer/BioNTech jab offering 88% protection against symptomatic disease with the Delta variant, compared with 94% protection against the Alpha variant. For the Oxford/AstraZeneca vaccine, the figures were 67% and 74% respectively.
Toki sitten vakavan sairastumisen osalta tilanne on huomattavasti parempi:
What about hospital admissions?
Protection against severe disease is a crucial metric, not least for assessing the potential pressures a new wave of infections could place on health services. The good news is that for this outcome the jabs appear to offer similar protection against both variants.
According to an analysis by PHE, the Pfizer/BioNTech jab was linked to a 94% vaccine effectiveness against hospital admission with the Delta variant after one dose and 96% after two doses, while the figures for the Oxford/AstraZeneca jab were 71% and 92% respectively.
This protection against hospital admission is similar to that for the Alpha variant, for which the Pfizer figures were 83% and 95% after the first and second jabs respectively, and 76% and 86% respectively for the AstraZeneca jab.